StockMarketWire.com - AstraZeneca said its results from a clinical trial assessing the company's chronic lymphocytic leukaemia drug had met its primary goal showing improved survival rates compared with the chemotherapy-based treatment.

Calquence, the company's chronic lymphocytic leukaemia treatment, in combination with obinutuzumab met its primary objective as results from thephase III ELEVATE-TN trial showed a 'statistically-significant and clinically-meaningful improvement' in progression-free survival when compared with the chemotherapy-based combination of chlorambucil and obinutuzumab, the company said.

The trial also met a key secondary endpoint showing Calquence monotherapy achieved a statistically-significant and clinically-meaningful improvement in progression-free survival compared to the chemotherapy and obinutuzumab regimen.

'These findings confirm the superiority of Calquence as a monotherapy and also in combination over standard-of-care treatments for chronic lymphocytic leukaemia. The positive results from both the ELEVATE-TN and ASCEND trials will serve as the foundation for regulatory submissions later this year,' said José Baselga, Executive Vice President, Oncology R&D.

AtraZeneca said it would present full results from the Phase III ASCEND clinical trial in relapsed or refractory chronic lymphocytic leukaemia as a late-breaking abstract at the upcoming European Hematology Association (EHA) Annual Congress on 16 June 2019.

Story provided by StockMarketWire.com